BioGaia AB - Year-end Report 2021
FOURTH QUARTER 2021 · Net sales amounted to SEK 206.2 million (187.6), an increase of 10% (excluding foreign exchange effects, 11%). · Net sales in the Paediatrics segment reached SEK 150.1 million (139.6), an increase of 8%. · Net sales in the Adult Health segment amounted to SEK 55.2 million (47.3), an increase of 17%. · Operating expenses amounted to SEK 105.9 million (94.7), an increase of 12%. Operating expenses included costs of evaluation of acquisition candidates of SEK 6.7 million and restructuring costs of SEK 5.7 million. Excluding these costs, operating expenses